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Abstract
Shiga toxins (Stxs) produced by Escherichia coli (STEC) cause systemic vascular damage, manifested as
hemolytic uremic syndrome in humans and as edema disease in pigs. Edema disease, a naturally occurring
disease of pigs, was used to determine whether Stx antibodies, administered after infection and after the onset
of Stx production, could prevent the systemic vascular damage and clinical disease caused by Stxs. A total of
119 STEC-infected pigs were treated with low, medium, or high doses of Stx antibody or with placebo. After
inoculation with STEC, antibodies or placebo was injected intraperitoneally at 2 days postinoculation (DPI;
low dose) or 4 DPI (medium and high doses). Edema disease was prevented with the low- and high-dose Stx
antibody treatments administered at 2 and 4 DPI, respectively. Highdose antibody treatment also reduced the
incidence and extent of vascular lesions. The degree of protection depended on the dose of antibody and the
time of administration.
Disciplines
Veterinary Medicine | Veterinary Microbiology and Immunobiology | Veterinary Preventive Medicine,
Epidemiology, and Public Health
Comments
This article is from Journal of Infectious Diseases 183 (2001): 347, doi:10.1086/317930.
Rights
Works produced by employees of the U.S. Government as part of their official duties are not copyrighted
within the U.S. The content of this document is not copyrighted.
Authors
Ilze Matise, Nancy A. Cornick, Sheridan L. Booher, James E. Samuel, Brad T. Bosworth, and Harley W. Moon
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/vmpm_pubs/97
347
CONCISE COMMUNICATION
Intervention with Shiga Toxin (Stx) Antibody after Infection by Stx-Producing
Escherichia coli
Ilze Matise,1 Nancy A. Cornick,1 Sheridan L. Booher,1
James E. Samuel,3 Brad T. Bosworth,2,a
and Harley W. Moon1
1Veterinary Medical Research Institute, Iowa State University,
and 2Enteric Diseases and Food Safety Research Unit, National
Animal Disease Center, US Department of Agriculture/Agricultural
Research Service, Ames; 3Department of Medical Microbiology
and Immunology, College of Medicine, Texas A&M University,
College Station
Shiga toxins (Stxs) produced by Escherichia coli (STEC) cause systemic vascular damage,
manifested as hemolytic uremic syndrome in humans and as edema disease in pigs. Edema
disease, a naturally occurring disease of pigs, was used to determine whether Stx antibodies,
administered after infection and after the onset of Stx production, could prevent the systemic
vascular damage and clinical disease caused by Stxs. A total of 119 STEC-infected pigs were
treated with low, medium, or high doses of Stx antibody or with placebo. After inoculation
with STEC, antibodies or placebo was injected intraperitoneally at 2 days postinoculation
(DPI; low dose) or 4 DPI (medium and high doses). Edema disease was prevented with the
low- and high-dose Stx antibody treatments administered at 2 and 4 DPI, respectively. High-
dose antibody treatment also reduced the incidence and extent of vascular lesions. The degree
of protection depended on the dose of antibody and the time of administration.
Shiga toxin (Stx)–producing Escherichia coli (STEC) strains
cause systemic vascular disease, manifested as hemolytic uremic
syndrome (HUS) [1, 2]. No specific treatment is currently avail-
able for HUS [2]. Stxs are the major virulence attributes of
STEC strains. HUS is frequently preceded by diarrhea and/or
hemorrhagic colitis (HC). HUS develops, on average, 6.5 days
after the onset of diarrhea [2], thus potentially providing a
postinfection window for intervention to prevent Stx-induced
systemic vascular damage and HUS. This concept was vali-
dated in the gnotobiotic pig model of E. coli O157:H7 infection
[3]. The success of passive immune treatment in that model
appears to depend on the time of treatment relative to the time
of infection.
Swine edema disease is another model for systemic disease
caused by STEC strains [4]. Edema disease is a naturally oc-
curring disease of weaned pigs, caused by host-adapted STEC
strains that produce a variant of Stx2 (Stx2e) [5]. The major
pathogenic events (toxin production in the intestine and sys-
temic vascular damage) in edema disease and HUS are similar.
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Clinical signs of edema disease develop several days after in-
fection, thus providing a potential postinfection window for
intervention, to prevent the vascular damage caused by Stxs.
Microscopically, the hallmark of edema disease is vascular ne-
crosis in the brain and gastrointestinal tract [5, 6]. In contrast
to HUS, renal damage is not a feature of edema disease. The
STEC strains associated with edema disease do not have the
attaching and effacing attribute characteristic of some, but not
all, STEC strains associated with HUS and HC [7].
Active or passive immunization against Stxs, before STEC
inoculation, prevents the systemic complications of STEC infec-
tion in animal models [3, 8–14]. Passive transfer of neutralizing
antibodies or active immunization with Stx2e toxoid protects pigs
against the lethal effects of Stx2e given intravenously [9].
We have characterized elsewhere [4] the temporal relation-
ships among colonization, Stx2e production, and the devel-
opment of systemic manifestations in edema disease. Stx2e was
detected in feces 1 day postinoculation (DPI). The mean time
from inoculation to the onset of clinical disease was 6 days.
The objectives of the study reported here were (1) to confirm
that the systemic effects of STEC infection in swine can be
prevented by postinfection treatment with Stx antibody and (2)
to extend the concept to a naturally occurring disease induced
by a host-adapted STEC strain and to treatment given several
days after the onset of Stx production in the intestine.
Materials and Methods
Antibody and placebo. Hyperimmune serum was produced by
vaccinating young adult pigs with genetically modified Stx2e (E167Q)
toxoid, as described elsewhere [8, 13]. In brief, pigs were vaccinated
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Table 1. Experimental design and incidence of clinical edema disease
in pigs inoculated with Shiga toxin 2e (Stx2e)–producing Escherichia
coli strain S1191 (infected pigs, ) or nonpathogenic E. colin p 119
strain 123 (control pigs, ).n p 38
Experiment
and group
Antibody (ab) treatment No. of pigs
Type Dose DPI Total Clinically ill
Experiment 1
Infected Placebo Low 2 30 9a
Infected Stx2e ab Low 2 30 0a
Control None NA NA 2 0
Control Stx2e ab Low 2 7 0
Experiment 2
Infected Placebo Medium 4 10 2
Infected Stx2e ab Medium 4 9 3
Control None NA NA 5 0
Control Stx2e ab Medium 4 5 0
Experiment 3
Infected Placebo High 4 20 7b
Infected Stx2e ab High 4 20 0b
Control None NA NA 9 0
Control Stx2e ab High 4 10 0
NOTE. Experiment 1 was performed with 3 replicates, experiment 2 with 1
replicate, and experiment 3 with 2 replicates. DPI, days postinoculation with E.
coli; NA, not applicable.
a Significant difference in disease outcome between these 2 groups ( ).P ! .01
b Significant difference in disease outcome between these 2 groups ( ).P ! .01
intramuscularly 4–7 times, at weekly intervals, with 50–500 mg of
toxoid in either Al2(OH)3 or Titer Max Gold (Sigma-Aldrich) ad-
juvant. Antibody was removed from serum by precipitation with
33% ammonium sulfate solution, as described elsewhere [9]. The titers
of the resulting Stx2e antibody preparations had a range of 2000–
100,000 log2. Serum for the placebo (Stx2e antibody titer !2 log2)
was collected from nonimmunized pigs.
Experimental design. Three experiments, with a total of 6 rep-
licates (table 1), were conducted, as described elsewhere [4]. Weaned
pigs were orally inoculated with 1010 cfu of STEC strain S1191
(infected pigs) or nonpathogenic E. coli 123 (control pigs). E. coli
S1191, which produces Stx2e, was isolated from a pig with edema
disease [4]. E. coli 123, a nonpathogenic isolate, was obtained from
a healthy pig.
Rectal swabs were collected from all pigs before and after in-
oculation. Rectal swabs were cultured on sheep blood agar, and
fecal samples were assayed for Stx2e, as described elsewhere [4].
Serum samples for Stx2e antibody assays were collected from all
pigs before inoculation, 1–2 days after antibody treatment, and at
the end of experiments. Serum samples were processed and assayed
as described elsewhere [4, 8]. The neutralizing titer was expressed
as a reciprocal of the highest dilution that neutralized 3–5 Vero
cytotoxin doses of Stx2e.
The objective of experiment 1 was to test whether a low-dose
antibody treatment would prevent edema disease if Stx2e antibod-
ies were given intraperitoneally at 2 DPI (table 1). The target anti-
body level to be attained was selected to approximate the protective
antibody levels attained by active immunization [13].
There was evidence of protection in experiment 1. Therefore, the
objective of experiment 2 was to test whether a medium dose of
antibody treatment would prevent edema disease if antibody treat-
ment was delayed to 4 DPI (table 1). The antibody dose given was
higher than that given in experiment 1.
There was no evidence of protection in experiment 2. Therefore,
the objective of experiment 3 was to extend experiment 2 with ad-
ministration of antibody at 4 DPI (table 1). Furthermore, the anti-
body dose was higher than that given in experiment 2.
Pigs were observed for signs of edema disease (i.e., subcutaneous
edema or neurologic impairment). Infected pigs that remained free
of clinical signs until the termination of experiments, 13–14 DPI,
were designated subclinical pigs. At necropsy, all pigs were examined
for gross lesions that are characteristic of edema disease and for
lesions indicative of concurrent disease. Brain-stem samples and sam-
ples obtained from 2 sites on the ileum (1 and 2 m proximal from
the ileocecal junction) were collected and preserved in formalin. Sec-
tions were examined microscopically for vascular necrosis. Slides
were coded such that the pathologist was blinded to the treatment
of the pigs. A tissue section was considered positive if it contained
>2 necrotic arteriolar profiles. A pig was considered positive if >1
tissue sample was scored positive. The percentage of necrotic arte-
riolar profiles per section was measured, to determine whether the
treatment had reduced the severity of disease in subclinical pigs.
Statistics. Fisher’s exact test (2 tailed), the x2 test, and the
Wilcoxon signed-rank test were used for data analysis. Results were
interpreted to be significantly different at . Whenever nu-P ! .05
merous tests of significance were done for a single data set, the
significance level was normalized by use of the Bonferoni method.
Results
STEC was not isolated from any pig before inoculation or
from controls 2 or 5 DPI. All pigs inoculated with strain S1191
shed the organism in feces. Stx2e was detected at 2 DPI in feces
from all of the 59 infected but none of the 29 control pigs so
examined (data not shown). Stx2e antibodies were not detected
in pigs before inoculation, and mean antibody titer remained
!2 log2 in the placebo-treated STEC-infected pigs and in non-
treated control pigs until the end of the experiments (figure 1).
Intraperitoneal administration of Stx2e antibody to the con-
trol and STEC-infected pigs resulted in a significant increase
in serum Stx2e antibody titers in infected pigs, in comparison
with those of placebo-treated infected pigs and nontreated con-
trol pigs ( , Wilcoxon signed-rank test; figure 1). Anti-P ! .05
body titers attained and sustained in antibody-treated control
and infected pigs were similar ( , Wilcoxon signed-P p .32–.83
rank test), decreasing slightly at the end of experiments in both
groups.
None of the control pigs exhibited clinical signs or had gross
lesions of edema disease. Clinical edema disease occurred in 21
(18%) of 119 STEC-infected pigs in experiments 1–3 (table 1).
On histological examination, none of the control pigs was found
to have vascular necrosis, whereas 89 (75%) of 119 infected pigs
had vascular necrosis. Layers of bacteria adherent to ileal villi
were seen in histological sections from 13 (11%) of 119 STEC-
infected pigs but not in any from the control pigs.
Experiment 1. Clinical disease occurred only in placebo-
treated STEC-infected pigs (table 1). The mean time of onset
of clinical disease was 7 DPI. The difference in the incidence
of clinical disease between antibody and placebo treatments
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Figure 1. Geometric mean of Shiga toxin 2e (Stx2e) antibody (ab) titers (in log2) of infected pigs (inoculated with Stx2e-producing Escherichia
coli strain S1191) and control pigs (inoculated with nonpathogenic E. coli strain 123). Pigs were treated with low (experiment [Exp] 1), medium
(Exp 2), or high (Exp 3) doses of Stx2e antibodies or placebo at 2 (Exp 1) or 4 (Exp 2 and 3) days after infection. Bars, SE.
was significant ( , 2-tailed Fisher’s exact test). The in-P ! .012
cidence and extent of vascular necrosis in Stx2e antibody–
treated and placebo-treated subclinical pigs were similar (76%
of antibody-treated subclinical pigs had lesions, with an average
of 25% of arterioles necrotic; 73% of placebo-treated subclinical
pigs had lesions, with an average of 15% of arterioles necrotic).
Experiment 2. The mean antibody titers attained were ∼10
times higher than those attained in experiment 1 ( , Wil-P ! .05
coxon signed-rank test; figure 1). Clinical disease occurred in
both antibody-treated and placebo-treated STEC-infected pigs
(table 1). The mean time of onset of clinical disease was 5 DPI.
All infected pigs that survived to the end of the study had
vascular lesions. Vascular lesions were extensive in both groups
(32% of arterioles necrotic in the antibody-treated group vs.
42% of arterioles necrotic in the placebo-treated group).
Experiment 3. The mean antibody titers attained in the
STEC-infected pigs of experiment 3 were significantly higher
than those attained in the STEC-infected pigs of experiment 2
( , Wilcoxon signed-rank test; figure 1). Clinical diseaseP ! .05
occurred only in placebo-treated STEC-infected pigs (table 1).
The mean time of onset of clinical disease was 7 DPI. The
difference in the incidence of clinical disease between antibody
and placebo treatments was significant ( , 2-tailed Fish-P ! .01
er’s exact test). In contrast to the first 2 experiments, the in-
cidence of vascular necrosis in antibody-treated subclinical pigs
was significantly lower than that of placebo-treated infected
pigs (30% and 85%, respectively; , x2 test). Additionally,P ! .01
the percentage of necrotic arterioles per section was reduced in
the antibody-treated group (6% in the antibody-treated group
vs. 32% in the placebo-treated group; , Wilcoxon signed-P ! .05
rank test).
Discussion
This study confirms the report that Stx-neutralizing anti-
bodies, given parenterally after infection, can protect pigs
against the systemic consequences of STEC infection [3]. This
study extends that observation to disease caused by a host-
adapted STEC strain in its natural host and extends the time
of intervention to 4 DPI. We exploited the time period after
infection and toxin production, but before the appearance of
clinical signs, as a window for intervention against systemic
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disease. In the edema disease model used here, the onset of Stx
production occurred during the first DPI [4]. Protection ap-
peared to depend on the dose of antibody and the time of
intervention. Protection was induced with a low dose of anti-
body given 2 DPI (>1 day after the onset of toxin production).
Protection was also induced at 4 DPI, but only when the highest
dose of antibody was given. This is consistent with evidence
that protection of actively immunized pigs against intravenous
Stx is antibody-titer dependent [9]. Our study supports the con-
cept that it may be possible to prevent the systemic effects of
Stx in humans with antibodies administered parenterally after
the patient is infected with or exposed to STEC.
In humans, intravenous administration of large boluses of
immunoglobulins poses the risk of inducing anaphylactoid re-
actions. These are attributed to immunoglobulin aggregates
formed during precipitation and fractionation of serum. Al-
though large amounts of immunoglobulins were given to the
pigs in this study, neither anaphylactoid reactions nor vascular
lesions indicative of immune complex–mediated vasculitis were
observed. Antibody titers remained stable in treated pigs for
the duration of the experiment, decreasing only slightly 10–12
days after the single injection. Although a reduction in the Stx2e
antibody titers in the STEC-infected pigs, in comparison with
control pigs, was expected (because of Stx2e antibody binding
to the circulating Stx2e), we found no evidence for it.
Subclinical edema disease, characterized by microscopic vas-
cular necrosis, is a consequence of STEC infection in pigs that
remain free of clinical signs [4, 6, 13]. It has been proposed
that, similarly, in humans infected with STEC, there may be
microscopic vascular lesions in the absence of HUS [15]. There-
fore, the effect of Stx2e antibody treatment on the incidence
and extent of vascular lesions in subclinically infected pigs was
assessed. We determined that protection against subclinical
edema disease apparently depended on the antibody dose. Only
the highest dose of Stx2e antibody reduced the incidence and
extent of vascular lesions in subclinically infected pigs.
In conclusion, this study demonstrated protection of pigs
against the systemic effects of STEC infection with passive anti-
body treatment given as late as 4 DPI. These results are con-
sistent with the hypothesis that passive immune therapy may
protect STEC-infected humans against systemic disease. Studies
are needed to determine whether passive antibodies protect
when administered at the time of onset of clinical edema disease.
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